Rosetta Inpharmatics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Rosetta Inpharmatics, Inc. - overview
Location
Kirkland, WA, US
Primary Industry
Biotechnology
About
Rosetta Inpharmatics, Inc. focuses on genomic research and development, providing insights into gene expression and its implications for health and disease. The company leverages advanced technologies to facilitate breakthroughs in personalized medicine. Rosetta Inpharmatics, Inc.
is dedicated to genomic research and the development of gene expression tools that aid in understanding health and disease relationships. The company was founded in Kirkland, US, and it underwent a significant strategic pivot when it was sold to Merck & Co. , Inc. in May 2001 for USD 620 mn, following its IPO in August 2000, which raised USD 100.
8 mn. The company has been involved in three total funding deals since its inception. Rosetta Inpharmatics offers a range of services centered on genomic discovery and bioinformatics, including tools for gene expression analysis and data management solutions. These services support pharmaceutical companies and researchers aiming to develop targeted therapies and improve health outcomes based on genetic insights.
In the most recent fiscal year, Rosetta Inpharmatics reported a revenue of USD 10,459,232. Despite a challenging economic environment, the company recorded an EBITDA of USD -31,013,554, reflecting ongoing investments in research and development to enhance its offerings. Following the successful acquisition by Merck & Co. , Inc.
, Rosetta Inpharmatics plans to enhance its product offerings in genomic research, with new tools anticipated for release by the end of 2022. The company aims to expand its market reach into Europe and Asia-Pacific by 2023, leveraging its latest funding from the Trade Sale in May 2001, amounting to USD 620 mn, to support these initiatives.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT, Analytics & Performance Software
Website
www.rii.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Rosetta Inpharmatics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Rosetta Inpharmatics, Inc. | - | ||||||||
| IPO | Completed | Rosetta Inpharmatics, Inc. | - | ||||||||
| Buyout | Completed | Rosetta Inpharmatics, Inc. | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.